✦ LIBER ✦

A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer

✍ Scribed by Zhao, Meng; Pan, Xueliang; Layman, Rachel; Lustberg, Maryam B.; Mrozek, Ewa; Macrae, Erin R.; Wesolowski, Robert; Carothers, Sarah; Puhalla, Shannon; Shapiro, Charles L.; Ramaswamy, Bhuvaneswari

Book ID: 125358961
Publisher: Springer US
Year: 2014
Tongue: English
Weight: 403 KB
Volume: 32
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-014-0122-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of bevacizumab in combi

A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer

✍ Lin, N. U.; Seah, D. S.; Gelman, R.; Desantis, S.; Mayer, E. L.; Isakoff, S.; Di 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 258 KB

Combination docetaxel and trastuzumab tr

Combination docetaxel and trastuzumab treatment for patients with her-2-overexpressing metastatic breast cancer: A multicenter, phase-II study

✍ Nobuaki Sato; Muneaki Sano; Toshio Tabei; Taro Asaga; Jiro Ando; Hirofumi Fujii; 📂 Article 📅 2006 🏛 Springer Japan 🌐 English ⚖ 553 KB

Pertuzumab plus trastuzumab and docetaxe

Pertuzumab plus trastuzumab and docetaxel in HER2-positive metastatic breast cancer

✍ Jame Abraham 📂 Article 📅 2012 🏛 Frontline Medical Communications, Inc. 🌐 English ⚖ 100 KB

A Phase II Study of Weekly Vinorelbine a

A Phase II Study of Weekly Vinorelbine and Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer

✍ Juan Lucas Bayo-Calero; José I. Mayordomo; Pedro Sánchez-Rovira; Ramón Pérez-Car 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 97 KB

Multicenter phase II study of trastuzuma

Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

✍ M. Venturini; C. Bighin; S. Monfardini; F. Cappuzzo; N. Olmeo; A. Durando; F. Pu 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 218 KB

AVEREL: A Randomized Phase III Trial Eva

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

✍ Gianni, Luca (author);Romieu, Gilles H. (author);Lichinitser, Michail (author);S 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 205 KB